Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.
  • Andrades Delgado, Álvaro|||0000-0001-9042-8964
  • Medina Vico, Pedro Pablo|||0000-0002-7834-7093
The authors thank Isabel Bartolessis (Cancer Genetics Group) at IJC for technical assistance. This work was supported by the Spanish Ministry of Economy and CompetitivityMINECO (grant number SAF-2017-82186R, to M.S.-C., and grant PI19/01320 to A. Villanueva) and from the Fundacion Cientifica of the Asociacion Espanola Contra el Cancer (AECC) (grant number GCB14142170MONT) to M.S.-C. A. Villanueva is also funded by the Department of Health of the Generalitat de Catalunya (2014SGR364). O.A. R. received a Juan de la Cierva postdoctoral contract (grant No. IJCI-2016-28201, until November 2019) and an AECC research contract (INVES19045ROME from December 2019). A. Vilarrubi, P.L. and A.A. are supported by pre-doctoral contracts from the Spanish MINECO (FPI-fellowship: PRE2018-084624, BES-2015-072204 and FPU17/00067). M.S. was supported by a Rio Hortega contract from the Instituto de Salud Carlos III (CM17/00180). L.F. received a European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Actions grant agreement, number 799850., Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients., Spanish Ministry of Economy and Competitivity-MINECO SAF-2017-82186R PI19/01320, Fundacion Cientifica of the Asociacion Espanola Contra el Cancer (AECC) GCB14142170MONT, Department of Health of the Generalitat de Catalunya 2014SGR364, Juan de la Cierva postdoctoral contract IJCI-2016-28201, AECC research contract INVES19045ROME, Spanish MINECO PRE2018-084624 BES-2015-072204 FPU17/00067, Instituto de Salud Carlos III European Commission CM17/00180, European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Actions grant agreement 799850
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

HTLV-1 proviral load in infective dermatitis associated with HTLV-1 does not increase after the development of HTLV-1-associated myelopathy/tropical spastic paraparesis and does not decrease after IDH remission

  • Batista, Everton S.
  • Oliveira, Pedro D.
  • Primo, Janeusa
  • Varandas, Cinthya Maria Neves
  • Nunes, Ana Paula
  • Bittencourt, Achiléa L.
  • Farré, Lourdes
Introduction Infective dermatitis associated with HTLV-1 (IDH) is a recurrent eczema which affects children vertically infected with HTLV-1. In Bahia, Brazil, we recently reported that 47% of IDH patients also develop juvenile HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive disabling disorder which is typically reported in adult HTLV-1 carriers. IDH may also predispose to adult T-cell leukemia/lymphoma, a neoplasm associated with HTLV-1. The factors relating to the development of HTLV-1-associated juvenile diseases have not yet been defined. HTLV-1 proviral load (PVL) is one of the main parameters related to the development of HTLV-1 associated diseases in adults. In the current study, we investigated the role of PVL in IDH and juvenile HAM/TSP. Methodology/Principal findings This is a cohort study that included fifty-nine HTLV-1 infected children and adolescents, comprising 16 asymptomatic carriers, 18 IDH patients, 20 patients with IDH and HAM/TSP (IDH/HAM/TSP) and five with HAM/TSP. These patients were followed-up for up to 14 years (median of 8 years). We found that PVL in IDH and IDH/HAM/TSP patients were similarly higher than PVL in juvenile asymptomatic carriers (p<0.0001). In those IDH patients who developed HAM/TSP during follow-up, PVL levels did not vary significantly. HAM/TSP development did not occur in those IDH patients who presented high levels of PVL. IDH remission was associated with an increase of PVL. Inter-individual differences in PVL were observed within all groups. However, intra-individual PVL did not fluctuate significantly during follow-up. Conclusions/Significance High PVL in IDH patients was not necessary indicative of progression to HAM/TSP. PVL did not decrease after IDH remission. The maintenance of high PVL after remission could favor early development of ATL. Therefore, IDH patients would have to be followed-up even after remission of IDH and for a long period of time., This work was supported by the Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB, www.fapesb.ba.gov.br) [Grant number RED0028/2012 to L.F.], Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, www.cnpq.br)[Grant number 409985/ 2016-3 to A.L.B.]. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Marie Curie grant (https://ec.europa.eu) [agreement number 799850 to L.F.] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero Ferraro, Octavio
  • Vilarrubi Porta, Andrea
  • Alburquerque Bejar, Juan J.
  • Gomez, Antonio
  • Andrades, Alvaro
  • Trastulli, Deborah
  • Pros, Eva
  • Setién, Fernando
  • Verdura, Sara
  • Farré, Lourdes
  • Martín-Tejera, Juan F.
  • Llabata, Paula
  • Oaknin, Ana
  • Saigí, Maria
  • Piulats, Josep M.
  • Matias-Guiu, Xavier, 1958-
  • Medina, Pedro P.
  • Vidal, August
  • Villanueva Garatachea, Alberto
  • Sánchez Céspedes, Montserrat
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Nadal, Ernest
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farré, Lourdes
  • McLean, Chelsea
  • Klarenbeek, Sjoerd
  • Jurgens, Anouk
  • Hagen, Hannes
  • Wang, Liqin
  • Felip, Enriqueta
  • Martínez Martí, Alex
  • Vidal-Bel, August
  • Voest, Emile
  • Wessels, Lodewyk F. A.
  • van Tellingen, Olaf
  • Villanueva Garatachea, Alberto
  • Bernards, René
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibidor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibidor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Clinicopathological aspects and proviral load of adulthood infective dermatitis associated with HTLV-1: Comparison between juvenile and adulthood forms

  • Souza, Lucca Santos
  • Silva, Thadeu Santos
  • de Oliveira, Maria de Fátima Paim
  • Farré, Lourdes
  • Bittencourt, Achileá Lisboa
Background Infective dermatitis associated with human T-cell lymphotropic virus type-1 (HTLV-1), (IDH), is a chronic eczema occurring in HTLV-1 infected children. Rare cases of adulthood IDH have been reported and no study until now aimed to compare juvenile and adulthood IDH. Methodology/Principal findings Twelve cases of adulthood IDH followed for a mean time of 7.5 years were analyzed according to clinicopathological and molecular aspects, comparing them to juvenile IDH cases. Diagnosis was based on the modified major criteria used for juvenile IDH. Proviral load (PVL) assessment was performed by real-time PCR technique. Adulthood IDH presented similar clinicopathological and molecular aspects compared to juvenile IDH. The morphology of lesions and areas of involvement were similar, except for the involvement of the ankles and inframammary folds in the adulthood form. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) occurred in six adulthood IDH patients, with almost equal frequency. However, at least in two patients, HAM/TSP appeared prior to IDH, differently from what was observed in juvenile IDH. Conclusions/Significance Adulthood IDH is similar to juvenile IDH according to clinicopathological aspects and PVL levels. Therefore, the same modified major diagnostic criteria for juvenile IDH can be applied to both forms., This work was supported by the Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (http://www.cnpq.br/), grant number 409985/2016-3, received by AL and by the Fundac¸ão de Amparo a Pesquisa do Estado da Bahia (http://www.fapesb.ba.gov.br), grant number 4345/2012. This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Marie Curie grant agreement num 799850 (LF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Nadal, Ernest
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farré, Lourdes
  • McLean, Chelsea
  • Klarenbeek, Sjoerd
  • Jurgens, Anouk
  • Hagen, Hannes
  • Wang, Liqin
  • Felip, Enriqueta
  • Martínez Martí, Alex
  • Vidal-Bel, August
  • Voest, Emile
  • Wessels, Lodewyk F. A.
  • van Tellingen, Olaf
  • Villanueva Garatachea, Alberto
  • Bernards, René
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibidor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibidor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinicopathological aspects and proviral load of adulthood infective dermatitis associated with HTLV-1: Comparison between juvenile and adulthood forms

  • Souza, Lucca Santos
  • Silva, Thadeu Santos
  • de Oliveira, Maria de Fátima Paim
  • Farré, Lourdes
  • Bittencourt, Achileá Lisboa
Background Infective dermatitis associated with human T-cell lymphotropic virus type-1 (HTLV-1), (IDH), is a chronic eczema occurring in HTLV-1 infected children. Rare cases of adulthood IDH have been reported and no study until now aimed to compare juvenile and adulthood IDH. Methodology/Principal findings Twelve cases of adulthood IDH followed for a mean time of 7.5 years were analyzed according to clinicopathological and molecular aspects, comparing them to juvenile IDH cases. Diagnosis was based on the modified major criteria used for juvenile IDH. Proviral load (PVL) assessment was performed by real-time PCR technique. Adulthood IDH presented similar clinicopathological and molecular aspects compared to juvenile IDH. The morphology of lesions and areas of involvement were similar, except for the involvement of the ankles and inframammary folds in the adulthood form. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) occurred in six adulthood IDH patients, with almost equal frequency. However, at least in two patients, HAM/TSP appeared prior to IDH, differently from what was observed in juvenile IDH. Conclusions/Significance Adulthood IDH is similar to juvenile IDH according to clinicopathological aspects and PVL levels. Therefore, the same modified major diagnostic criteria for juvenile IDH can be applied to both forms., This work was supported by the Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (http://www.cnpq.br/), grant number 409985/2016-3, received by AL and by the Fundac¸ão de Amparo a Pesquisa do Estado da Bahia (http://www.fapesb.ba.gov.br), grant number 4345/2012. This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Marie Curie grant agreement num 799850 (LF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HTLV-1 proviral load in infective dermatitis associated with HTLV-1 does not increase after the development of HTLV-1-associated myelopathy/tropical spastic paraparesis and does not decrease after IDH remission

  • Batista, Everton S.
  • Oliveira, Pedro D.
  • Primo, Janeusa
  • Varandas, Cinthya Maria Neves
  • Nunes, Ana Paula
  • Bittencourt, Achiléa L.
  • Farré, Lourdes
Introduction Infective dermatitis associated with HTLV-1 (IDH) is a recurrent eczema which affects children vertically infected with HTLV-1. In Bahia, Brazil, we recently reported that 47% of IDH patients also develop juvenile HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a progressive disabling disorder which is typically reported in adult HTLV-1 carriers. IDH may also predispose to adult T-cell leukemia/lymphoma, a neoplasm associated with HTLV-1. The factors relating to the development of HTLV-1-associated juvenile diseases have not yet been defined. HTLV-1 proviral load (PVL) is one of the main parameters related to the development of HTLV-1 associated diseases in adults. In the current study, we investigated the role of PVL in IDH and juvenile HAM/TSP. Methodology/Principal findings This is a cohort study that included fifty-nine HTLV-1 infected children and adolescents, comprising 16 asymptomatic carriers, 18 IDH patients, 20 patients with IDH and HAM/TSP (IDH/HAM/TSP) and five with HAM/TSP. These patients were followed-up for up to 14 years (median of 8 years). We found that PVL in IDH and IDH/HAM/TSP patients were similarly higher than PVL in juvenile asymptomatic carriers (p<0.0001). In those IDH patients who developed HAM/TSP during follow-up, PVL levels did not vary significantly. HAM/TSP development did not occur in those IDH patients who presented high levels of PVL. IDH remission was associated with an increase of PVL. Inter-individual differences in PVL were observed within all groups. However, intra-individual PVL did not fluctuate significantly during follow-up. Conclusions/Significance High PVL in IDH patients was not necessary indicative of progression to HAM/TSP. PVL did not decrease after IDH remission. The maintenance of high PVL after remission could favor early development of ATL. Therefore, IDH patients would have to be followed-up even after remission of IDH and for a long period of time., This work was supported by the Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB, www.fapesb.ba.gov.br) [Grant number RED0028/2012 to L.F.], Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, www.cnpq.br)[Grant number 409985/ 2016-3 to A.L.B.]. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Marie Curie grant (https://ec.europa.eu) [agreement number 799850 to L.F.] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero Ferraro, Octavio
  • Vilarrubi Porta, Andrea
  • Alburquerque Bejar, Juan J.
  • Gomez, Antonio
  • Andrades, Alvaro
  • Trastulli, Deborah
  • Pros, Eva
  • Setién, Fernando
  • Verdura, Sara
  • Farré, Lourdes
  • Martín-Tejera, Juan F.
  • Llabata, Paula
  • Oaknin, Ana
  • Saigí, Maria
  • Piulats, Josep M.
  • Matias-Guiu, Xavier, 1958-
  • Medina, Pedro P.
  • Vidal, August
  • Villanueva Garatachea, Alberto
  • Sánchez Céspedes, Montserrat
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition

  • Oliveira-Mateos, Cristina|||0000-0003-2574-7816
  • Sánchez Castillo, Anaís|||0000-0003-4024-976X
  • Soler, Marta|||0000-0002-6656-957X
  • Obiols-Guardia, Aida|||0000-0002-2548-8597
  • Piñeyro, David|||0000-0001-5633-3339
  • Boque-Sastre, Raquel|||0000-0002-0214-8848
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Rubio Lopez, Maria Teresa|||0000-0003-0843-528X
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Herrero-Martín, David|||0000-0001-6548-6812
  • Tirado, Oscar M.|||0000-0002-4666-2822
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Esteller, M.|||0000-0003-4490-6093
  • Farré, Lourdes|||0000-0002-3168-1940
  • Guil, Sonia|||0000-0002-2257-3331
One largely unknown question in cell biology is the discrimination between inconsequential and functional transcriptional events with relevant regulatory functions. Here, we find that the oncofetal HMGA2 gene is aberrantly reexpressed in many tumor types together with its antisense transcribed pseudogene RPSAP52. RPSAP52 is abundantly present in the cytoplasm, where it interacts with the RNA binding protein IGF2BP2/IMP2, facilitating its binding to mRNA targets, promoting their translation by mediating their recruitment on polysomes and enhancing proliferative and self-renewal pathways. Notably, downregulation of RPSAP52 impairs the balance between the oncogene LIN28B and the tumor suppressor let-7 family of miRNAs, inhibits cellular proliferation and migration in vitro and slows down tumor growth in vivo. In addition, high levels of RPSAP52 in patient samples associate with a worse prognosis in sarcomas. Overall, we reveal the roles of a transcribed pseudogene that may display properties of an oncofetal master regulator in human cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.|||0000-0002-0549-8835
  • Nadal, Ernest|||0000-0002-9674-5554
  • Bosdriesz, Evert|||0000-0002-8788-9548
  • Ooft, Salo N.|||0000-0002-3990-3376
  • Farré, Lourdes|||0000-0002-3168-1940
  • McLean, Chelsea|||0000-0002-3548-3482
  • Klarenbeek, Sjoerd
  • Jurgens, Anouk
  • Hagen, Hannes
  • Wang, Liqin
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Vidal, August|||0000-0001-5727-2099
  • Voest, Emile|||0000-0001-8249-9586
  • Wessels, Lodewyk F. A.
  • van Tellingen, Olaf|||0000-0002-1037-6269
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bernards, Rene|||0000-0001-8677-3423
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy. A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.|||0000-0003-0229-6530
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Andrades, Álvaro
  • Trastulli, Deborah|||0000-0003-2407-3290
  • Pros, Eva|||0000-0002-2366-7866
  • Setien, Fernando|||0000-0002-4061-4635
  • Verdura, Sara|||0000-0001-8980-0423
  • Farré, Lourdes|||0000-0002-3168-1940
  • Martín-Tejera, Juan F.
  • Llabata, Paula|||0000-0001-7733-6475
  • Oaknin, Ana|||0000-0002-3592-7194
  • Saigí, Maria|||0000-0001-5815-5388
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Medina, Pedro P.
  • Vidal, August|||0000-0001-5727-2099
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome, Combined molecular and therapeutic studies

  • Farré, Lourdes|||0000-0002-3168-1940
  • Sanz-Linares, Gabriela|||0000-0001-7960-7988
  • Ruiz-Xivillé, Neus
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Martin-Tejera, Juan Francisco|||0000-0002-8060-3578
  • Goncąlves-Ribeiro, Samuel|||0000-0002-0261-3965
  • Martinez-Iniesta, Maria
  • Calaf, Monica
  • Mosquera, José Luis|||0000-0002-7852-4993
  • Martin-Subero, Jose Ignacio|||0000-0001-8809-5195
  • Granada, Isabel|||0000-0002-4275-0104
  • Esteller, M.|||0000-0003-4490-6093
  • Domingo-Domenech, Eva|||0000-0001-8907-090X
  • Climent, Fina|||0000-0002-4360-8388
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sureda, Anna|||0000-0002-1238-6970
Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well-characterized preclinical models for EMM are not available. Herein, a patient-derived orthotopic xenograft (PDOX) was generated from a patient with an aggressive EMM to study in-depth genetic and epigenetic events, and drug responses related to extramedullary disease. A fresh punch of an extramedullary cutaneous lesion was orthotopically implanted in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ(NSG) mouse. The PDOX mimicked histologic and phenotypic features of the tumor of the patient. Cytogenetic studies revealed a hyperploid genome with multiple genetic poor-prognosis alterations. Copy number alterations (CNAs) were detected in all chromosomes. The IGH translocation t(14;16)(q32;q23)IGH/MAF was already observed at the medullary stage and a new one, t(10;14)(p?11-12;q32), was observed only with extramedullary disease and could be eventually related to EMM progression in this case. Exome sequencing showed 24 high impact single nucleotide variants and 180 indels. From the genes involved, only TP53 was previously described as a driver in MM. A rather balanced proportion of hyper/hypomethylated sites different to previously reported widespread hypomethylation in MM was also observed. Treatment with lenalidomide, dexamethasone and carfilzomib showed a tumor weight reduction of 90% versus nontreated tumors, whereas treatment with the anti-CD38 antibody daratumumab showed a reduction of 46%. The generation of PDOX from a small EMM biopsy allowed us to investigate in depth the molecular events associated with extramedullary disease in combination with drug testing.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.